Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

Parkinson Disease Clinical Trial

Official title:

Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01358474
• Other study ID #: 10-DAT-003
• Status: Completed
• Start date: July 2011
• Est. completion date: December 2018

Study information

• Verified date: April 2019
• Source: University of Minnesota - Clinical and Translational Science Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine if participants have changes in dopamine cells in their brain using DaTSCAN™ brain imaging. Dopamine cell loss occurs in Parkinson's disease (PD) and other degenerative Parkinsonian disorders, but does not occur in most other movement disorders such as essential tremor or dystonia. DaTSCAN, which is also known as 123I-Ioflupane, is a new compound that has been developed by General Electric, Inc. and has been approved by the US Food and Drug Administration (FDA) to help doctors detect changes in dopamine. This test is performed by injecting DaTSCAN into a vein in the arm, and after a few hours, a large amount of DaTSCAN temporarily accumulates in an area of the brain where there are a lot of dopamine brain cells. Because DaTSCAN contains a small amount of radioactive iodine, it allows doctors to use a special machine called single photon emission computed tomography (SPECT) scanning to detect the location and amount of radioactivity in the brain and help determine if there are changes in brain dopamine. It is hoped that this study will help doctors detect the presence of dopamine changes even before symptoms are present. This study will evaluate DaTSCAN in people with PD, those who are at risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations) and those who are healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: December 2018
• Est. primary completion date: October 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Written consent prior to study by the subject or their surrogate

• Subjects >/= 18 years and</=85 years

• Diagnosis of Parkinson's disease, family history of Parkinson's disease, idiopathic rapid eye movement sleep behavioral disorder, age-matched controls, Gaucher's disease or carrier of Gaucher's gene mutation

• Females using adequate methods of birth control or not of childbearing potential

Exclusion Criteria:

• Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination

• Any exposure to investigational drugs within 4 weeks prior to Visit 1

• Any exposure to radiopharmaceuticals within 4 weeks prior to Visit 1

• Pregnancy

• Breastfeeding

• Severe swallowing problems

• Known sensitivity or allergy to iodine containing products

• Advanced liver or renal disease

Related Conditions & MeSH terms

• Gaucher Disease
• Idiopathic Rapid Eye Movement Sleep Disorder
• Parasomnias
• Parkinson Disease
• Parkinsonian Disorders
• Sleep Wake Disorders

Locations

Country	Name	City	State
United States	University of Minnesota, Center for Magnetic Resonance Research	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Minnesota - Clinical and Translational Science Institute	GE Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	single photon computed tomography (SPECT) imaging following administration of a visual adjunct imaging agent that detects dopamine loss		Visit 1